

## Literatura ACTA MEDICINAE 11–13/2025 Onkologie | Hematoonkologie | Hematologie

- 3 [Lze věřit v přenositelnost dat mezi populacemi?](#)  
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň
- 3 [WCLC 2025 a nemalobuněčný karcinom plic](#)  
MUDr. Leona Koubková Pneumologická klinika, 2. LF UK a FN Motol, Praha
- 3 [Adjuvantní léčba rizikového karcinomu prsu](#)  
doc. MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika, 1. LF UK a VFN Praha
- 3 [Léčba metastatického triple negativního karcinomu prsu talazoparibem, dlouhodobá odpověď u pacientky s germinální mutací BRCA2 – kazuistika](#)  
MUDr. Kateřina Jirsová Onkologická klinika, FN Motol, Praha; Onkologické oddělení, Nemocnice Na Pleši, s. r. o.
- 3 [Trastuzumab deruxtecan v léčbě metastatického HER2-low karcinomu prsu – kazuistika](#)  
MUDr. Jan Šustr, Ph.D. Onkologická a radioterapeutická klinika, FN Plzeň
- 4 [Systémová léčba metastatického karcinomu endometria](#)  
MUDr. Denisa Pohanková, Ph.D. | MUDr. Zdeněk Zoul Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové  
MUDr. Munachiso Onyedikachi Nduwke | MUDr. Petra Bretová, Ph.D. | doc. MUDr. Taťána Rešlová, CSc. | prof. MUDr. Jiří Špaček, Ph.D. Porodnická a gynekologická klinika, LF UK a Fakultní nemocnice Hradec Králové  
doc. MUDr. Igor Sirák, Ph.D. Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové
- 4 [Pokročilý ovariální karcinom: je bevacizumab stále optimálním komparátorem v éře nových možností léčby?](#)  
MUDr. Munachiso Ndukwe Porodnická a gynekologická klinika, Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové  
MUDr. Petra Bretová, Ph.D. | MUDr. Ivan Práznovec Porodnická a gynekologická klinika, LF UK a Fakultní nemocnice Hradec Králové  
MUDr. Denisa Pohanková | doc. MUDr. Igor Sirák, Ph.D. Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové
- 4 [Pembrolizumab a lenvatinib u recidivujícího karcinomu endometria – naše první zkušenosti – kazuistiky](#)  
MUDr. Jan Kümmel Onkogynekologické centrum GPK, FN Ostrava
- 5 [Moderní biologická léčba metastatického renálního karcinomu](#)  
doc. MUDr. Alexandr Poprach, Ph.D. | doc. MUDr. Radek Lakomý, Ph.D. | MUDr. Peter Staňo Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno
- 5 [Úspěšná léčba pacienta s lokálně pokročilým inoperabilním renálním karcinomem kombinací pembrolizumabu a lenvatinibu – kazuistika](#)  
MUDr. Věra Benešová Komplexní onkologické centrum, Nemocnice Jihlava
- 5 [Adjuvantní imunoterapie karcinomu ledviny – kazuistika](#)  
MUDr. Mgr. Markéta Dvořáková Onkologická klinika, 2. LF UK a FN Motol, Praha
- 5 [Pacient s pokročilým metastatickým světlobuněčným renálním karcinomem léčeným kombinací pembrolizumabu a lenvatinibu – kazuistika](#)  
doc. MUDr. Alexandr Poprach, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno  
MUDr. Kateřina Stiskalová Oddělení radiologie, Masarykův onkologický ústav a LF MU, Brno  
MUDr. Jan Holoubek Oddělení radiační a klinické onkologie, Nemocnice Znojmo
- 6 [Management kardiovaskulárního rizika farmakologické terapie karcinomu prostaty](#)  
prof. MUDr. Radek Pudil, Ph.D., FESC I. interní kardioangiologická klinika, LF UK a FN Hradec Králové
- 6 [Durvalumab v perioperační léčbě svalově invazivního karcinomu močového měchýře: výsledky studie NIAGARA](#)  
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň
- 6 [Onkofertilita](#)  
MUDr. Jan Vodička, Ph.D. Gynekologicko-porodnická klinika, FN Olomouc, Lékařská fakulta UP v Olomouci

- 6 **Od progresu ke kompletní remisi: úspěšná léčba pemigatinibem u pacienta s metastazujícím FGFR2 pozitivním cholangiocarcinomem – kazuistika**  
MUDr. Kateřina Bohuňovská Ústav radiační onkologie, 1. LF UK a FN Bulovka, Praha
- 7 **Léčba karcinomu intrahepatálních a extrahepatálních žlučových cest: současný stav, novinky a směry vývoje**  
MUDr. Štěpán Tuček, Ph.D. Interní hematologická a onkologická klinika, FN Brno a LF Masarykovy univerzity, Brno
- 7 **Postavení inhibitorů Brutonovy tyrosinkinázy v léčbě lymfomu z buněk pláště**  
MUDr. Andrea Hrušková | MUDr. Aleš Obr, Ph.D. Hemato-onkologická klinika, FN Olomouc a LF UP v Olomouci
- 8 **Bispecifické protilátky v terapii nehodgkinských lymfomů**  
MUDr. Kamila Polgárová, Ph.D. Interní klinika – klinika hematologie, 1. LF UK a VFN Praha
- 9 **Možnosti terapie CAR-T v léčbě lymfomů v roce 2025 v České republice**  
MUDr. František Folber, Ph.D. Interní hematologická a onkologická klinika, FN Brno a LF MU, Česká společnost pro genovou a buněčnou terapii, ČLS JEP  
MUDr. Martina Filipová Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno
- 9 **Kam se posouvá léčba nemocných s nehodgkinskými lymfomy v roce 2025**  
doc. MUDr. David Belada, Ph.D. IV. interní hematologická klinika, LF UK a FN Hradec Králové
- 9 **Terapeutická zkušenost s ponatinibem u pacienta s refrakterní chronickou myeloidní leukemií – kazuistika**  
MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie, 1. LF UK, Praha
- 10 **Dosažení stabilní odpovědi na terapii fostamatinibem u pacienta s multirefrakterní imunitní trombocytopenií – kazuistika**  
MUDr. Eva Konířová I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 10 **Molekulární diagnostika hematoonkologických onemocnění: zkušenosti z laboratoře GHC Genetics**  
Mgr. Tomáš Píší | Mgr. Kristýna Hanuláková GHC Genetics, s. r. o., Praha
- 10 **Bispecifické protilátky v léčbě folikulárního lymfomu**  
MUDr. Pavla Štěpánková IV. interní hematologická klinika, LF UK a FN Hradec Králové

# Lze věřit v přenositelnost dat mezi populacemi?

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň

- 1 Cheng, Y., et al.: Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer. The ASTRUM-005 randomized clinical trial. *JAMA*, 2022, 328, s. 1223–1232.
- 2 Cheng, Y., et al.: Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005). 2022 ESMO Asia, abstrakt LBA9, dostupné z: <https://slide.ctimeetingtech.com/asia2022/attendee/confcal/session/calendar?q=cheng>, vyhledáno 13. 8. 2025.
- 3 A randomized, double-blind, placebo controlled phase III study to investigate efficacy and safety of HLX10 + chemotherapy (carboplatin- etoposide) in patients with extensive stage small cell lung cancer (ES-SCLC). Dostupné z: <https://clinicaltrials.gov/study/NCT04063163>, vyhledáno 13. 8. 2025.

## WCLC 2025 a nemalobuněčný karcinom plic

MUDr. Leona Koubková Pneumologická klinika, 2. LF UK a FN Motol, Praha

- 1 Planchard, D. – Jänne, P. A. – Kobayashi, K., et al.: First-line osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. Prezentováno na IASLC 2025 World Conference on Lung Cancer, 6.–9. 9. 2025, Barcelona, Španělsko, abstrakt 1956.
- 2 Wakelee, H. A. – Demeds, I. – Langleben, A., et al.: Perioperative pembrolizumab in non-small cell cancer (NSCLC): 4-year outcomes by nodal status in the KEYNOTE-671 study. Prezentováno na IASLC 2025 World Conference on Lung Cancer, 6.–9. 9. 2025, Barcelona, Španělsko, abstrakt MA04.04.

## Adjuvantní léčba rizikového karcinomu prsu

doc. MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika, 1. LF UK a VFN Praha

- 1 O'Shaughnessy, J. – Tolaney, S. M. – Yardley, D. A., et al.: Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer. *Breast*, 2025, 81, 104437.
- 2 Curigliano, G. C. – Kalinsky, K. – Proudman, D., et al.: Short-term risk of recurrence in patients with HR+/HER2- early breast cancer treated with endocrine therapy in randomized clinical trials: a meta-analysis. *J Clin Oncol*, 2024, 42, suppl. 16, s. 541–541.
- 3 Pan, H. – Gray, R. – Braybrooke, J., et al.: 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med*, 2017, 377, s. 1836–1846.
- 4 Piccart, M. – van't Veer, L. J. – Poncet, C., et al.: 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase III randomized MINDACT trial with an exploratory analysis by age. *Lancet Oncol*, 2021, 22, s. 476–488.
- 5 Kalinsky, K. – Barlow, W. E. – Meric-Bernstam, F., et al.: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy ± chemotherapy in patients with 1–3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score ≤25: SWOG S1007 (RxPONDER). *J Clin Oncol*, 2021, 39, suppl. 18, LBA1.
- 6 Geyer, C. E. Jr. – Blum, J. L. – Yothers, G., et al.: Long term follow up of anthracycline containing regimens in early breast cancer: USOR 06 090, NSABP B46 /USOR 07132, and NSABP B 49 (NRG Oncology). *J Clin Oncol*, 2024, 42, s. 1344–1349.
- 7 Chen, N. – Gluz, O. – Pérez, E. A., et al.: Impact of anthracyclines plus taxane-based chemotherapy for certain patients at high risk for breast cancer recurrence: post hoc TAILORx analysis. Prezentováno jako abstrakt GS3 03 na 2024 San Antonio Breast Cancer Symposium; San Antonio, TX.
- 8 Gluz, O. – Nitz, U. – Christgen, M., et al.; West German Study Group (WSG) ADAPT Investigators: Prognostic impact of recurrence score, endocrine response and clinicopathological factors in high risk luminal breast cancer: results from the WSG ADAPT HR+/HER2- chemotherapy trial. *J Clin Oncol*, 2021, 39, suppl. 15, 504.
- 9 Johnston, S. R. D. – Toi, M. – O'Shaughnessy, J., et al.: Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarch): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2023, 24, s. 77–90.
- 10 Hortobagyi, G. N. – Lacko, A. – Sohn, J., et al.: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer (NATALEE): final invasive disease free survival results. *Ann Oncol*, 2025, 36, s. 149–157.
- 11 Harbeck, N. – Gluz, O. – Christgen, M., et al.: ADAPTCycle: adjuvant dynamic marker adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer. *J Clin Oncol*, 2020, 38, suppl. 15, TPS601-TPS601.
- 12 Pistilli, B. – Lohrisch, C. – Sheade, J., et al.: Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer. *Am Soc Clin Oncol Educ Book/ASCO*, 2022, 42, s. 60–72.
- 13 Regan, M. M. – Francis, P. A. – Pagani, O., et al.: Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. *J Clin Oncol*, 2016, 34, s. 2221–2231.
- 14 Ditsch, N. – Wöcke, A. – Untch, M., et al.: AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2022. *Breast Care*, 2022, 17, s. 403–420.
- 15 Dumas, E. – Jochum, F. – Coussy, F., et al.: Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study. *J Clin Oncol*, 2025, 43, s. 1863–1874.
- 16 Piccart-Gebhart, M. J. – Procter, M. – Leyland-Jones, B., et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *NEJM*, 2005, 353, s. 1659–1672.
- 17 Perez, E. A. – Romond, E. H. – Suman, V. J., et al.: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. *J Clin Oncol*, 2011, 29, s. 3366–33673.
- 18 van der Voort, A. – van Ramshorst, M. S. – van Werkhoven, E. D., et al.: Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN 2 randomized, phase 3 trial. *JAMA Oncol*, 2021, 7, s. 700–708.
- 19 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 20 von Minckwitz, G. – Procter, M. – de Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *NEJM*, 2017, 377, s. 122–131.
- 21 von Minckwitz, G. – Huang, C. S. – Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *NEJM*, 2019, 380, s. 617–628.
- 22 Moon, S. – Bae, S. J. – Kook, Y., et al.: 233MO Ovarian function suppression in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial. *Ann Oncol*, 2024, 35, suppl. 2, S310.
- 23 De Graaf, M. – de Boer, M. – van Seijen, M., et al.: MO236 Real-world outcomes of early triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy ± immune checkpoint inhibition (ICI): A Dutch population-based study. 13.–17. 9. 2024, ESMO 2024.
- 24 Schmid, P. – Cortes, J. – Dent, R., et al.: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high risk early stage triple negative breast cancer: overall survival results from the Phase III KEYNOTE 522 study. *Ann Oncol*, 2024, 35, s. S1204–S1205.
- 25 Masuda, N. – Lee, S. J. – Ohtani, S., et al.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *NEJM*, 2017, 376, s. 2147–2159.
- 26 Tutt, A. N. J. – Garber, J. E. – Kaufman, B., et al.: Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *NEJM*, 2021, 384, s. 2394–2405.

## Léčba metastatického triple negativního karcinomu prsu talazoparibem, dlouhodobá odpověď u pacientky s germinální mutací BRCA2 – kazuistika

MUDr. Kateřina Jirsová Onkologická klinika, FN Motol, Praha; Onkologické oddělení, Nemocnice Na Pleši, s. r. o.

- 1 Foulkes, W. D. – Smith, I. E. – Reis-Filho, J. S.: Triple-negative breast cancer. *N Engl J Med*, 2010, 363, s. 1938–1948, doi: 10.1056/NEJMa1001389.
- 2 Cortesi, L. – Rugo, H. S. – Jackisch, C.: An overview of PARP inhibitors for the treatment of breast cancer. *Targeted Oncology*, 2021, 16, s. 255–282, doi: 10.1007/s11523-021-00796-8.
- 3 Litton, J. K., et al.: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med*, 2018, 379, s. 753–763, doi: 10.1056/NEJMoA1802905.

## Trastuzumab deruxtecan v léčbě metastatického HER2-low karcinomu prsu – kazuistika

MUDr. Jan Šustr, Ph.D. Onkologická a radioterapeutická klinika, FN Plzeň

- 1 Hurvitz, S. A. – Hegg, R. – Chung, W. P., et al.: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. *Lancet*, 2023, 401, s. 105–117, doi: 10.1016/S0140-6736(22)02420-5.
- 2 Cortés, J. – Hurvitz, S. A. – Im, S. A., et al.: Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. *Nat Med*, 2024, 30, s. 2208–2215, doi: 10.1038/s41591-024-03021-7.
- 3 Modi, S. – Jacot, W. – Yamashita, T., et al.: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med*, 2022, 387, s. 9–20, doi: 10.1056/NEJMoA2203690.

# Systemová léčba metastatického karcinomu endometria

MUDr. Denisa Pohanková, Ph.D. | MUDr. Zdeněk Zoul Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové

MUDr. Munachiso Onyedikachi Nduwke | MUDr. Petra Bretová, Ph.D. | doc. MUDr. Taťána Rešlová, CSc. |

prof. MUDr. Jiří Špaček, Ph.D. Porodnická a gynekologická klinika, LF UK a Fakultní nemocnice Hradec Králové

doc. MUDr. Igor Sirák, Ph.D. Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové

- 1 Dostupné z: <https://www.svod.cz/incidence-mortalita>, vyhledáno 15. 5. 2025.
- 2 Restaino, S. – Paglietti, C. – Arcieri, M., et al.: Management of patients diagnosed with endometrial cancer: comparison of guidelines. *Cancers*, 2023, 15, 1091.
- 3 Makker, V. – MacKay, H. – Ray-Coquard, I., et al.: Endometrial cancer. *Nat Rev Dis Primer*, 2021, 7, 88.
- 4 Salmon, A. – Lebeau, A. – Streef, S., et al.: Locally advanced and metastatic endometrial cancer: Current and emerging therapies. *Cancer Treat Rev*, 2024, 129, 102790.
- 5 Wellenstein, M. D. – Coffelt, S. B. – Duits, D. E. M., et al.: Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. *Nature*, 2019, 572, s. 538–542.
- 6 Powell, M. A. – Bjorge, L. – Willmott, L., et al.: Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. *Ann Oncol*, 2024, 35, s. 728–738.
- 7 Eskander, R. N. – Sill, M. W. – Belfa, L., et al.: Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med*, 2023, 388, s. 2159–2170.
- 8 Westin, S. N. – Moore, K. – Chon, H. S., et al.: Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. *J Clin Oncol*, 2024, 42, s. 283–299.
- 9 Mirza, M. R. – Coleman, R. L. – Hanker, L., et al.: 820TIP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC). *Ann Oncol*, 2021, 32, s. S770–S771.
- 10 Makker, V. – Colombo, N. – Casado Herráez, A., et al.: Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. *J Clin Oncol*, 2023, 41, s. 2904–2910, doi:10.1200/JCO.22.02152.
- 11 O'Malley, D. M. – Bariani, G. M. – Cassier, P. A., et al.: Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. *J Clin Oncol*, 2022, 40, s. 752–761.
- 12 Oaknin, A. – Gilbert, L. – Tinker, A. V., et al.: Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET – a phase I, single-arm study. *J Immunother Cancer*, 2022, 10, e003777.
- 13 Mirza, M. R. – Bjorge, L. – Marmé, F.: A randomised double-blind placebo-controlled phase II trial of pembrolizumab combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): ESMO Virtual Congr 2020. 2020, 31, S1160.
- 14 Colon-Otero, G. – Zafagnin, V. – Hou, X., et al.: Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. *ESMO Open*, 2020, 5, e000926.
- 15 Konstantinopoulos, P. A. – Lee, E. K. – Xiong, N., et al.: A phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer. *J Clin Oncol*, 2023, 41, s. 599–608.
- 16 Aghajanian, C. – Sill, M. W. – Darcy, K. M., et al.: Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. *J Clin Oncol*, 2011, 29, s. 2259–2265.
- 17 Simpkins, F. – Drake, R. – Escobar, P. F., et al.: A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). *Gynecol Oncol*, 2015, 136, s. 240–245.
- 18 Vergote, I. – Powell, M. A. – Teneriello, M. G., et al.: Second-line lenvatinib in patients with recurrent endometrial cancer. *Gynecol Oncol*, 2020, 156, s. 575–582.
- 19 Makker, V., et al.: A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111/KEYNOTE-146): long-term efficacy and safety update. *J Clin Oncol*, 2023, 41, s. 974–979.
- 20 Fader, A. N. – Roque, D. M. – Siegel, E., et al.: Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. *Clin Cancer Res*, 2020, 26, s. 3928–3935.

## Pokročilý ovariální karcinom: je bevacizumab stále optimálním komparátorem v éře nových možností léčby?

MUDr. Munachiso Nduwke Porodnická a gynekologická klinika, Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové

MUDr. Petra Bretová, Ph.D. | MUDr. Ivan Práznovec Porodnická a gynekologická klinika, LF UK a Fakultní nemocnice Hradec Králové

MUDr. Denisa Pohanková | doc. MUDr. Igor Sirák, Ph.D. Klinika onkologie a radioterapie, LF UK a Fakultní nemocnice Hradec Králové

- 1 Sung, H. – Ferlay, J. – Siegel, R. L., et al.: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer J Clin*, 2021, 71, s. 209–249.
- 2 Dochez, V. – Caillon, H. – Vaucel, E., et al.: Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *J Ovarian Res*, 2019, 12, 28.
- 3 Gadducci, A. – Cosio, S.: Randomized clinical trials and real world prospective observational studies on bevacizumab, PARP inhibitors, and immune checkpoint inhibitors in the first-line treatment of advanced ovarian carcinoma: a critical review. *Anticancer Res*, 2021, 41, s. 4673–4685.
- 4 Sedláková I.: A new opportunity in ovarian cancer treatment. *Ceska Gynekol*, 2012, 77, s. 469–471.
- 5 Burger, R. A. – Brady, M. F. – Bookman, M. A., et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*, 2011, 365, s. 2473–2483.
- 6 Perren, T. J. – Swart, A. M. – Pfisterer, J., et al.: A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*, 2011, 365, s. 2484–2496.
- 7 Moore, K. – Colombo, N. – Scambia, G., et al.: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2018, 379, s. 2495–2505.
- 8 González-Martín, A. – Pothuri, B., et al.: Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2019, 381, s. 2391–2402.
- 9 Ray-Coquard, I. – Pautier, P. – Pignata, S., et al.: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med*, 2019, 381, s. 2416–2428.
- 10 Harter, P. – Bidziński, M. – Colombo, N., et al.: DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. *J Clin Oncol*, 2019, 37, TPS5598–TPS5598.
- 11 Monk, B. J. – Coleman, R. L. – Fujiwara, K., et al.: ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. *Int J Gynecol Cancer*, 2021, 31, ijc-2021-002933.
- 12 Hardy-Bessard, A.-C. – Moore, K. N. – Mirza, M. R., et al.: ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). *J Clin Oncol*, 2020, 38, TPS6101–TPS6101.
- 13 Liu, J. – Berchuck, A. – Backes, F. J., et al.: NCCN Guidelines Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines. *J Natl Compr Cancer Netw*, 2024, 22, s. 512–519.
- 14 González-Martín, A. – Harter, P. – Leary, A., et al.: Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2023, 34, s. 833–848.

## Pembrolizumab a lenvatinib u recidivujícího karcinomu endometria – naše první zkušenosti – kazuistiky

MUDr. Jan Kümmel Onkogynekologické centrum GPK, FN Ostrava

- 1 Kwok, G. – Yau, T. C. – Chiu, J. W., et al.: Pembrolizumab (Keytruda). *Hum Vaccin Immunother*, 2016, 12, s. 2777–2789, doi: 10.1080/21645515.2016.1199310.
- 2 Motzer, R. J. – Taylor, M. H. – Evans, T. R. J., et al.: Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. *Expert Rev Anticancer Ther*, 2022, 22, s. 383–400, doi: 10.1080/14737140.2022.2039123.
- 3 Makker, V. – Colombo, N. – Casado Herráez, A., et al.: Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. *J Clin Oncol*, 2023, 41, s. 2904–2910, doi: 10.1200/JCO.22.02152.
- 4 Makker, V. – Colombo, N. – Casado Herráez, A., et al.: Study 309+KEYNOTE-775 Investigators: Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*, 2022, 386, s. 437–448, doi: 10.1056/NEJMoa2108330.
- 5 Colombo, N. – Lorusso, D. – Monk, B. J., et al.: Characterization and management of adverse reactions in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab. *Oncologist*, 2024, 29, s. 25–35, doi: 10.1093/oncolo/oyad201.
- 6 SmPC Lenvima.
- 7 SmPC Keytruda.

# Moderní biologická léčba metastatického renálního karcinomu

doc. MUDr. Alexandr Poprach, Ph.D. | doc. MUDr. Radek Lakomý, Ph.D. | MUDr. Peter Staňo  
Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno

- Heng, D. Y. C. – Xie, W. – Regan, M. M., et al.: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol*, 2009, 27, s. 5794–5799.
- Choueiri, T. K. – Penkov, K. – Uemura, H., et al.: Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. *Ann Oncol*, 2025, 36, s. 387–392.
- Fei, C. – Zhen, X. – Shiqiang, Z., et al.: Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma. *Cell Death Discov*, 2024, 10, s. 1–13.
- Tannir, N. M. – Albiges, L. – McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. *Ann Oncol*, 2024, 35, s. 1026–1038.
- Choueiri, T. K. – Eto, M. – Motzer, R., et al.: Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. *Lancet Oncol*, 2023, 24, s. 228–238.
- Choueiri, T. K. – Hessel, C. – Halabi, S., et al.: Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. *Eur J Cancer*, 2018, 94, s. 115–125.
- Kao, T.-W. – Bai, G.-H. – Wang, T.-L., et al.: Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. *J Experiment Clin Cancer Res*, 2023, 42, 171.
- Vasudev, N. S. – Ainsworth, G. – Brown, S., et al.: Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). *JCO*, 2024, 42, s. 312–323.
- Msaouel, P. – Yu, K. – Yuan, Y., et al.: Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase I trial. *Nat Commun*, 2025, 16, 578.
- Takamatsu, K. – Tanaka, N. – Matsumoto, K., et al.: Uncovering LAG-3 related tumor immunology in renal cell carcinoma and pan-cancer evaluation. *JCO*, 2023, 41, e16517–e16517.
- Takamatsu, K. – Tanaka, N. – Hakozi, K., et al.: Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. *Nat Commun*, 2021, 12, 5547.
- Pal, S. K. – Tran, B. – Haanen, J. B. A. G., et al.: CD70-targeted allogeneic CART-T-cell therapy for advanced clear cell renal cell carcinoma. *Cancer Discov*, 2024, 14, s. 1176–1189.
- Correa, A. F. – Kalashnikova, E. – Wu, H.-T., et al.: Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma. *Oncologist*, 2024, 29, s. 887–893.
- Büchler, T. – Poprach, A.: Planned discontinuation of tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma: lessons for the era of immunotherapy. *Targ Oncol*, 2024, 19, s. 175–180.
- Ornstein, M. C. – George, L. – Wei, W., et al.: Phase II trial of intermittent therapy in patients with metastatic renal cell carcinoma treated with front-line ipilimumab and nivolumab. *Clin Genitourin Cancer*, 2024, 22, 102181.
- Meza, L. – Feng, M. – Lee, K., et al.: The gut microbiome and metastatic renal cell carcinoma. *J Clin Med*, 2023, 12, 1502.
- Hoerner, C. R. – Chen, V. J. – Fan, A. C.: The 'Achilles heel' of metabolism in renal cell carcinoma: glutaminase inhibition as a rational treatment strategy. *Kidney Cancer*, 2019, <https://doi.org/10.3233/KCA-180043>.

a ESMO-MCBS v1.1 was used to calculate scores for therapies/indications approved by the EMA or FDA. The scores have been calculated and validated by the ESMOMCBS Working Group and reviewed by the authors. Dostupné z: <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms>, vyhledáno 6. 5. 2025.

## Úspěšná léčba pacienta s lokálně pokročilým inoperabilním renálním karcinomem kombinací pembrolizumabu a lenvatinibu – kazuistika

MUDr. Věra Benešová Komplexní onkologické centrum, Nemocnice Jihlava

- [www.linkos.cz](http://www.linkos.cz)
- Powles, T. – Albiges, L. – Bex, A., et al.: ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2024, 35, s. 692–706.
- NCCN Clinical Practice Guidelines in Oncology, Kidney Cancer v. 2. 2025.

## Adjuvantní imunoterapie karcinomu ledviny – kazuistika

MUDr. Mgr. Markéta Dvořáková Onkologická klinika, 2. LF UK a FN Motol, Praha

- Aggarwal, G. – Gupta, S. – Khwaunju, P.: Hypercalcemia in urological malignancies: A review. *Türk J Urol*, 2022, 48, s. 243–253.
- Choueiri, T. K. – Eto, M. – Motzer, R., et al.: Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. *Lancet Oncol*, 2023, 24, s. 228–238.
- Grünwald, V. – McKay, R. R. – Buchler, T., et al.: Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. *Int J Cancer*, 2024, s. 1–10.

## Pacient s pokročilým metastatickým světlobuněčným renálním karcinomem léčným kombinací pembrolizumabu a lenvatinibu – kazuistika

doc. MUDr. Alexandr Poprach, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno

MUDr. Kateřina Stiskalová Oddělení radiologie, Masarykův onkologický ústav a LF MU, Brno

MUDr. Jan Holoubek Oddělení radiční a klinické onkologie, Nemocnice Znojmo

- Powles, T. – Albiges, L. – Bex, A., et al.: Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2024, 35, s. 692–706.
- Motzer, R. J. – Jonasch, E. – Agarwal, N., et al.: Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guideline for Oncology. *J Natl Compr Canc Netw*, 2022, 20, s. 71–90.
- Janowitz, T. – Welsh, S. J. – Zaki, K., et al.: Adjuvant therapy in renal cell carcinoma – past, present, and future. *Semin Oncol*, 2021, 48, s. 72–86.
- Haas, N. B. – Manola, J. – Uzzo, R. G., et al.: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ASSURE). *Lancet*, 2017, 387, s. 2008–2016.
- Motzer, R. J. – Haas, N. B. – Donskov, F., et al.: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in localized or locally advanced RCC (PROTECT). *J Clin Oncol*, 2017, 35, s. 3916–3923.
- Ravaud, A. – Motzer, R. J. – Pandha, H. S., et al.: Adjuvant sunitinib in high-risk RCC after nephrectomy: S-TRAC. *N Engl J Med*, 2016, 375, s. 2246–2254.
- Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *N Engl J Med*, 2021, 385, s. 683–694.
- Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.: Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. *N Engl J Med*, 2023, 389, s. 1233–1243.
- Escudier, B. – Porta, C. – Schmidinger, M., et al.: Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 676–689.
- Escudier, B. – Porta, C. – Schmidinger, M., et al.: Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 676–689.
- NCCN Guidelines: Kidney Cancer. Version 2.2025.
- Motzer, R. J. – Jonasch, E. – Agarwal, N., et al.: Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 2022, 20, s. 71–90.
- ÚZIS ČR: Novotvary 2019–2021. Praha, Ústav zdravotnických informací a statistiky ČR, 2023, [www.uzis.cz](http://www.uzis.cz).
- SVOD – Epidemiologie zhoubných nádorů v ČR. Aktualizace 2024, [www.svod.cz](http://www.svod.cz).
- Escudier, B. – Porta, C. – Schmidinger, M., et al.: Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 676–689.
- Bolek, H. – Ůrún, Y.: Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions. *Crit Rev Oncol Hematol*, 2023, 192, doi: 10.1016/j.critrevonc.2023.104144.
- Peters, S. – Salgia, R. – Reck, M., et al.: PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. *Lung Cancer*, 2018, 116, s. 117–125.

# Management kardiovaskulárního rizika farmakologické terapie karcinomu prostaty

prof. MUDr. Radek Pudil, Ph.D., FESC I. interní kardiologická klinika, LF UK a FN Hradec Králové

- 1 Krejčí, D. – Mrázek, J. – Dušek, L.: Cancer incidence 2019–2021 in the Czech Republic. Ústav zdravotnických informací a statistiky, 2021, dostupné z: <https://www.uzis.cz/index.php?pg=registry-sber-dat-narodni-zdravotni-registry--narodni-onkologicky-registr#publikace>, vyhledáno 16. 9. 2025.
- 2 Lyon, A. R. – Lopez-Fernandez, T. – Couch, L. S., et al.: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*, 2022, 43, s. 4229–4361.
- 3 Leong, D. P. – Fradet, V. – Shayegan, B., et al.: Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. *J Urol*, 2020, 203, s. 1109–1116.
- 4 Crawford, E. D. – Hafron, J. M. – Debruyne, F., et al.: Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. *J Urol*, 2024, 211, s. 63–70.
- 5 Poljak, Z. – Hulin, I. – Maruscakova, L., et al.: Are GnRH and FSH potentially damaging factors in the cardiovascular system? *Pharmazie*, 2018, 73, s. 187–190.
- 6 Salem, J. E. – Waintraub, X. – Courtilot, C., et al.: Hypogonadism as a reversible cause of torsades de pointes in men. *Circulation*, 2018, 138, s. 110–113.
- 7 Basaria, S.: Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. *J Androl*, 2008, 29, s. 534–539.
- 8 Mahal, B. A. – D'Amico, A. V. – Nguyen, P. L. Re: Shore, N. D. – Saad, F. – Cookson, M. S., et al.: Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. *N Engl J Med*, 2020, 382, s. 2187–2196.
- 9 Lopes, R. D. – Higano, C. S. – Slovin, S. F., et al.: Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. *Circulation*, 2021, 144, s. 1295–1307.

# Durvalumab v perioperační léčbě svalově invazivního karcinomu močového měchýře: výsledky studie NIAGARA

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň

- 1 Powles, T. – Catto, J. W. F. – Galsky, M. D., et al.: Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. *N Engl J Med*, 2024, 391, s. 1773–1786.

## Onkofertilita

MUDr. Jan Vodička, Ph.D. Gynekologicko-porodnická klinika, FN Olomouc, Lékařská fakulta UP v Olomouci

- 1 Siegel, R. L. – Miller, K. D. – Jemal, A.: Cancer statistics, 2020. *CA Cancer J Clin*, 2020, 70, s. 7–30, doi: 10.3322/caac.21590.
- 2 Poorvu, P. D. – Frazier, A. L. – Ferao, A. M., et al.: Cancer treatment-related infertility: a critical review of the evidence. *JNCI Cancer Spectr*, 2019, 3, doi: 10.1093/jncics/pkz008.
- 3 Santaballa, A. – Marquez-Vega, C. – Rodriguez-Lescure, A., et al.: Multidisciplinary consensus on the criteria for fertility preservation in cancer patients. *Clinical and Translational Oncology*, 2022, 24, s. 227–243, doi: 10.1007/s12094-021-02699-2.
- 4 European Society of Human Reproduction and Embryology: Female Fertility Preservation Guideline of the European Society of Human Reproduction and Embryology 2020. 2022. Dostupné z: <https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Female-fertility-preservation>, vyhledáno 30. 9. 2025.
- 5 Cedars, M. I.: Evaluation of female fertility – AMH and ovarian reserve testing. *J Clin Endocrinol Metab*, 2022, 107, s. 1510–1519, doi: 10.1210/clinem/dgac039.
- 6 Lee, S. J. – Schover, L. R. – Partridge, A. H., et al.: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol*, 2006, 24, s. 2917–2931, doi: 10.1200/JCO.2006.06.5888.
- 7 Meistrich, M. L.: Risk of genetic damage in offspring conceived using spermatozoa produced during chemotherapy or radiotherapy. *Andrology*, 2020, 8, s. 545–558, doi: 10.1111/and.12740.
- 8 Lambertini, M. – Horicks, F. – Del Mastro, L., et al.: Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical applications. *Cancer Treat Rev*, 2019, 72, s. 65–77, doi: 10.1016/j.ctrv.2018.11.006.
- 9 Dolmans, M. M. – Taylor, H. S. – Rodriguez-Wallberg, K. A., et al.: Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons. *Fertil Steril*, 2020, 114, s. 725–738, doi: 10.1016/j.fertnstert.2020.08.011.
- 10 Munoz, M. – Santaballa, A. – Segui, M. A., et al.: SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients. *Clin Transl Oncol*, 2016, 18, s. 1229–1236, doi: 10.1007/s12094-016-1587-9.
- 11 Skinner, R. – Mulder, R. L. – Kremer, L. C., et al.: Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *Lancet Oncol*, 2017, 18, s. e75–e90, doi: 10.1016/S1470-2045(17)30026-8.
- 12 Duma, N. – Lambertini, M.: It is time to talk about fertility and immunotherapy. *Oncologist*, 2020, 25, s. 277–278, doi: 10.1634/theoncologist.2019-0837.
- 13 Krejčí, D. – Mužík, J. – Dušek, L., et al.: Současné epidemiologické trendy novotvarů v České republice. Dostupné z: [www.uzis.cz/res/f/0084477/novotvary2019-2021.pdf](https://www.uzis.cz/res/f/0084477/novotvary2019-2021.pdf), vyhledáno 8. 10. 2025.
- 14 Marklund, A. – Eloranta, S. – Wikander, I., et al.: Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer: a prospective nationwide Swedish multicenter study. *Hum Reprod*, 2020, 35, s. 929–938, doi: 10.1093/humrep/deaa029.
- 15 Hlászová, N. – Crha, I. – Huser, M., et al.: Zachování fertility u žen s karcinomem prsu před gonadotoxickou léčbou. *Ceska Gynekol*, 2017, 82, s. 287–292.
- 16 Multicenter Study: Fertility preservation and assisted reproduction in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy. *J Clin Oncol*, 2024, 42, s. 2822–2832, doi: 10.1200/JCO.23.02292.
- 17 Cibula, D. – Potter, R. – Planchamp, F., et al.: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the management of patients with cervical cancer. *Virchows Arch*, 2018, 472, s. 19–936, doi: 10.1007/s00428-018-2362-9.
- 18 Fichtinger, M. – Rodriguez-Wallberg, K. A.: Fertility preservation in women with cervical, endometrial or ovarian cancers. *Gynaecol Oncol Res Pract*, 2016, 3, s. 8, doi: 10.1186/s40661-016-0029-2.
- 19 Krassas, G. E. – Pontikides, N.: Gonadal effect of radiation from I131 in male patients with thyroid carcinoma. *Arch Androl*, 2005, 51, s. 171–175, doi: 10.1080/014850190898746.
- 20 Viviani, S. – Santoro, A. – Ragni, G., et al.: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: comparative results of MOPP vs ABVD. *Eur J Cancer Clin Oncol*, 1985, 21, s. 601–605, doi: 10.1016/0277-5379(85)90088-4.
- 21 Hoekman, E. J. – Broeders, E. A. – Louiwe, L. A., et al.: Ovarian function after ovarian transposition and additional pelvic radiotherapy: a systematic review. *Eur J Surg Oncol*, 2019, 45, s. 1328–1340, doi: 10.1016/j.ejso.2019.02.017.
- 22 Mardešić, T. – Jelínková, L. – Melicharová, L.: Úspěšná transplantace ovariální tkáně u pacientky s ovariálním selháním po onkologické léčbě. *Ceska Gynekol*, 2017, 82, s. 38–41.
- 23 Hoekman, E. J. – Louwe, L. A. – Rooijers, M., et al.: Ovarian tissue cryopreservation: low usage rates and high live-birth rate after transplantation. *Acta Obstet Gynecol Scand*, 2020, 99, s. 213–221, doi: 10.1111/aogs.13735.
- 24 Tomilová, M. – Fruhaufová, K.: Zachování fertility u onkologických pacientek. *Ceska Gynekol*, 2022, 87, s. 356–361, doi: 10.48095/ccccg2022356.
- 25 Haggar, F. A. – Pereira, G. – Preen, D., et al.: Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. *PLoS One*, 2014, 9, e113292, doi: 10.1371/journal.pone.0113292.
- 26 Alon, I.: Mapping ethical, legal, and social implications (ELSI) of fertility preservation. *J Assist Reprod Genet*, 2024, 41, s. 2495–2514, doi: 10.1007/s10815-024-03210-w.

# Od progresu ke kompletní remisi: úspěšná léčba pemigatinibem u pacienta s metastazujícím FGFR2 pozitivním cholangiokarcinomem – kazuistika

MUDr. Kateřina Bohuňovská Ústav radiční onkologie, 1. LF UK a FN Bulovka, Praha

- 1 Saverno, K. – Zimmerman Savill, K. M. – Brown-Bickerstaff, Ch., et al.: Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US. *Oncologist*, 2025, 30, oyae204.
- 2 Abou-Alfa, G. K. – Sahai, V. – Hollebecque, A., et al.: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A Multicentre, open-label, phase 2 study. *Lancet Oncol*, 2020, 21, s. 671–684.
- 3 Nghiem, V. – Wood, S. – Ramchandran, R., et al.: Short- and long-term survival of metastatic biliary tract cancer in the United States from 2000 to 2018. *Cancer Control*, 2023, 30, 10732748231211764.
- 4 Lindley, A. – Prager, G. – Bitzer, M., et al.: Global expanded access program for pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma and fibroblast growth factor receptor gene alterations. *Cancer Res Treat*, 2024, 56, s. 847–855.

# Léčba karcinomu intrahepatálních a extrahepatálních žlučových cest: současný stav, novinky a směry vývoje

MUDr. Štěpán Tuček, Ph.D. Interní hematologická a onkologická klinika, FN Brno a LF Masarykovy univerzity, Brno

- 1 Valle, J. – Wasan, H. – Palmer, D. H., et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02): a phase 3 randomised trial. *N Engl J Med*, 2010, 362, s. 1273–1281, doi: 10.1056/NEJMoa0908721.
- 2 Oh, D. Y. – He, A. R. – Qin, S., et al.: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1). *NEJM Evid*, 2022, 1, EVIDoa2200015, doi: 10.1056/EVIDoa2200015.
- 3 Oh, D. Y. – He, A. R. – Qin, S., et al.: Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. *J Hepatol*, 2025, S0168-8278(25)02201-9, doi: 10.1016/j.jhep.2025.05.003.
- 4 Primrose, J. N. – Fox, R. P. – Palmer, D. H., et al.: Capecitabine compared with observation in resected biliary tract cancer (BILCAP). *Lancet Oncol*, 2019, 20, s. 663–673.
- 5 Vogel, A. – Bridgewater, J. – Edeline, J., et al.: Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2023, 34, s. 127–140.
- 6 Oh, D. Y. – He, A. R. – Qin, S., et al.: Durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. *Lancet Gastroenterol Hepatol*, 2024, 9, s. 694–704.
- 7 Lamarca, A. – Palmer, D. H. – Wasan, H. S., et al.: Oxaliplatin/5-FU/leucovorin (mFOLFOX) versus active symptom control after progression on cisplatin/gemcitabine in advanced biliary tract cancer (ABC-06). *Lancet Oncol*, 2021, 22, s. 690–701, doi: 10.1016/S1470-2045(21)00027-9.
- 8 Davids, P. H. – Groen, A. K. – Rauws, E. A., et al.: Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. *Lancet*, 1992, 340, s. 1488–1492, doi: 10.1016/0140-6736(92)92752-2.
- 9 Jang, S. – Stevens, T. – Parsi, M. A., et al.: Self-expandable metallic stents versus plastic stents in malignant distal biliary stricture: comparative outcomes. *Clin Gastroenterol Hepatol*, 2022, 20, s. 2301–2310.e7, doi: 10.1016/j.cgh.2020.12.022.
- 10 Mocan, T. – Horhat, A. – Mois, E., et al.: Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: when and how? *World J Gastroenterol*, 2021, 27, s. 8140–8158, doi: 10.3748/wjg.v27.i48.8140.
- 11 Leng, J. – Zhang, N. – Dong, J., et al.: Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary obstruction: a meta-analysis. *J Cancer Res Ther*, 2014, 10, suppl. 1, s. C200–C205, doi: 10.4103/0973-1482.145841.
- 12 Niemelä, J. – Syrjälä, H. – Ohtonen, P., et al.: Impact of cholangitis on survival of patients with malignant biliary obstruction treated with percutaneous transhepatic biliary drainage. *BMC Gastroenterol*, 2023, 23, 120, doi: 10.1186/s12876-023-02704-8.
- 13 Abou-Alfa, G. K. – Macarulla, T. – Javle, M. M., et al.: Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a phase 3, randomised, double-blind, placebo-controlled study. *Lancet Oncol*, 2020, 21, s. 796–807, doi: 10.1016/S1470-2045(20)30157-1.
- 14 U. S. Food and Drug Administration. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with FGFR2 rearrangement or fusion. 17. 4. 2020, www.fda.gov.
- 15 European Medicines Agency. Pemazyre (pemigatinib) – EPAR; conditional approval 26. 3. 2021, www.ema.europa.eu.
- 16 Abou-Alfa, G. K. – Sahai, V. – Hollebecq, A., et al.: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma (FIGHT-202). *Lancet Oncol*, 2020, 21, s. 671–684, doi: 10.1016/S1470-2045(20)30109-1.
- 17 Harding, J. J. – Fan, J. – Oh, D. Y., et al.: Zanidatamab for HER2-amplified biliary tract cancer (HERIZON-BTC-01): a phase 2b study. *Lancet Oncol*, 2023, 24, s. 772–782, doi: 10.1016/S1470-2045(23)00242-5.
- 18 U. S. Food and Drug Administration. FDA grants accelerated approval to zanidatamab-hrii for previously treated, HER2-positive biliary tract cancer. 21. 11. 2024, www.fda.gov.
- 19 European Commission/EMA. Ziihera (zanidatamab) – conditional approval in the EU. 27. 6. 2025, www.ema.europa.eu.
- 20 Piha-Paul, S. A. – Sahebjam, S. – Ren, C., et al.: First-in-human study of tinengotinib (TT-00420). *Oncologist*, 2024, 29, s. e514–e525.
- 21 ClinicalTrials.gov. SAFIR-ABC10 (NCT05615818): maintenance targeted therapy in advanced biliary tract cancer. www.clinicaltrials.gov.
- 22 Oh, D. Y. – Qin, S. – He, A. R., et al.: Updated overall survival from TOPAZ-1. *Lancet Gastroenterol Hepatol*, 2024, 9, s. 694–704, doi: 10.1016/S2468-1253(24)00095-5.
- 23 U. S. Food and Drug Administration. Futibatinib accelerated approval for FGFR2-rearranged intrahepatic cholangiocarcinoma. 30. 9. 2022, www.fda.gov.
- 24 European Medicines Agency. Lytgobi (futibatinib) – conditional marketing authorisation 4. 7. 2023, www.ema.europa.eu.

## Postavení inhibitorů Brutonovy tyrosinkinázy v léčbě lymfomu z buněk pláště

MUDr. Andrea Hrušková | MUDr. Aleš Obr, Ph.D. Hemato-onkologická klinika, FN Olomouc a LF UP v Olomouci

- 1 Krejčí, D. – Mužík, J. – Dušek, L.: Novotvary 2019–2021 ČR. Současné epidemiologické trendy novotvarů v České republice. Dostupné z: <https://www.uzis.cz/res/ff/008447/novotvary2019-2021.pdf>, vyhledáno 7. 7. 2025.
- 2 Alaggio, R., et al.: The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. *Leukemia*, 2022, 36, s. 1720–1748.
- 3 Hoster, E., et al.: Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. *J Clin Oncol*, 2014, 32, s. 1338–1346.
- 4 Silkenstedt, E. – Linton, K. – Dreyling, M.: Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches. *Br J Haematol*, 2021, 195, s. 162–173.
- 5 Tian, G. – Chen, Z. – Wang, B., et al.: Small-molecule BTK inhibitors: From discovery to clinical application. *Bioorganic Chem*, 2025, 157, 108242.
- 6 Nakhoda, S. – Vistarop, A. – Wang, Y.-L.: Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. *Br J Haematol*, 2023, 200, s. 137–149.
- 7 Wang, M. L., et al.: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. *Blood*, 2015, 126, s. 739–745.
- 8 Rule, S., et al.: Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. *Haematologica*, 2019, 104, s. e211–e214.
- 9 Obr, A., et al.: Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. *Ann Hematol*, 2023, 102, s. 107–115.
- 10 Arun Kumar, S. – Gao, J. – Patel, S. A.: The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma. *Leuk Res*, 2023, 134, 107385.
- 11 Eyre, T. A. – Cheah, Ch. Y. – Wang, M. L.: Therapeutic options for relapsed/refractory mantle cell lymphoma. *Blood*, 2022, 139, s. 666–677.
- 12 Dreyling, M., et al.: A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. *Future Oncol*, 2021, 17, s. 255–262.
- 13 Telaraja, D., et al.: FDA Approval Summary: pirtobrutinib for relapsed or refractory mantle cell lymphoma. *Clin Cancer Res*, 2024, 30, s. 17–22.
- 14 Dreyling, M., et al.: Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. *Lancet*, 2024, 403, s. 2293–2306.
- 15 Dreyling, M., et al.: Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. *Blood*, 2024, 144, suppl. 1, 240.
- 16 Wang, M. L., et al.: Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. *N Engl J Med*, 2022, 386, s. 2482–2494.
- 17 Wang, M., et al.: Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. *J Clin Oncol*. 2025 May 13:CO2500690.
- 18 Lewis, D. J., et al.: Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: results from the international randomised controlled trial, Enrich. *Blood*, 2024, 144, suppl. 1, 235.
- 19 Jerkeman, M., et al.: Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trial. *Blood*, 2024, 144, suppl. 1, s. 747–748.
- 20 Le Gouill, S., et al.: Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. *Blood*, 2021, 137, s. 877–887.
- 21 Le Gouill, S., et al.: Ibrutinib, venetoclax plus CD20 monoclonal Ab provides very high MRD negativity in previously untreated MCL patients, initial results of OASIS II, a randomized phase 2 trial. *Blood*, 2024, 144, suppl. 1, 745.
- 22 Wang, M., et al.: Acalabrutinib plus venetoclax and rituximab in treatment-naïve mantle cell lymphoma: 2-year safety and efficacy analysis. *Blood Adv*, 2024, 8, s. 4539–4548.
- 23 Kumar, A., et al.: Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. *Blood*, 2025, 145, s. 497–507.
- 24 Gouill, S. L., et al.: Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. *Haematologica*, 2024, 109, s. 343–350.
- 25 Song, Y., et al.: Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. *Blood*, 2022, 139, s. 3148–3158.
- 26 Cai, L. – Roos, J. – Paulo, M., et al.: Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma. *J Med Econ*, 2024, 27, s. 1552–1557.
- 27 Handunnetti, S. M., et al.: Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. *Blood*, 2024, 144, s. 867–872.
- 28 Wang, M., et al.: Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2025, 26, s. 200–213.
- 29 Forsgren, E., et al.: Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial. *HemaSphere*, 2025, 9, e70101.
- 30 Novak, U., et al.: Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). *eClinicalMedicine*, 2023, 64, 102221.
- 31 Phillips, T., et al.: Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial. *Haematologica*, 2025, 110, s. 715–724.
- 32 Melani, C., et al.: Phase 1b/2 study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory and treatment-naïve mantle cell lymphoma: preliminary analysis of safety, efficacy, and minimal residual disease. *Blood*, 2024, 144, suppl. 1, 750–750.
- 33 Mato, A. R., et al.: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *Lancet*, 2021, 397, s. 892–901.
- 34 Shah, N. N., et al.: Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. *Haematologica*, 2025, 110, s. 92–102.
- 35 Cohen, J. B., et al.: Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTK: safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study. *Blood*, 2023, 142, suppl. 1, 981–981.
- 36 Deng, L.-J., et al.: Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. *Blood Adv*, 2023, 7, s. 4349–4357.
- 37 Woyach, J. A., et al.: First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. *Cancer Discov*, 2024, 14, s. 66–75.
- 38 McLaughlin, N., et al.: Central nervous system involvement by mantle cell lymphoma. *Blood*, 2021, 138, suppl. 1, s. 2426–2426.
- 39 Rusconi, C., et al.: Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. *Blood*, 2022, 140, s. 1907–1916.
- 40 Tucker, D.-L. – Naylor, A. – Kruger, A., et al.: Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi-centre case series from the United Kingdom. *Br J Haematol*, 2017, 178, s. 327–329.
- 41 Hess, G., et al.: Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. *Br J Haematol*, 2023, 202, s. 749–759.
- 42 Jain, N., et al.: Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents. *J Hematol Oncol*, 2023, 16, 99.
- 43 Alsuhebyani, N. – Pan, C. – Holovac, E., et al.: Zanubrutinib in mantle cell lymphoma management: a comprehensive review. *Blood Lymphat Cancer*, 2023, 13, s. 67–76.

# Bispesifické protilátky v terapii ne Hodgkinových lymfomů

MUDr. Kamila Polgárová, Ph.D. Interní klinika – klinika hematologie, 1. LF UK a VFN Praha

- Plosker, G. L. – Figgitt, D. P.: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. *Drugs*, 2003, 63, s. 803–843.
- Cerny, T. – Borisch, B. – Introna, M., et al.: Mechanism of action of rituximab. *Anticancer Drugs*, 2002, 13, suppl. 2, s. S3–10.
- Sun, Y. – Yu, X. – Wang, X., et al.: Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. *Acta Pharm Sin B*, 2023, 13, s. 3583–3597.
- Kuchnio, A. – Yang, D. – Vloeemans, N., et al.: Characterization of JNJ-80948543, a novel CD79b/CD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma. *Blood*, 2022, 140, s. 3105–3106.
- Schjesvold, F. – Jelinek, T. – Polgarova, K., et al.: First-in-human phase 1 study of SAR442257 in patients with relapsed/refractory multiple myeloma and non-Hodgkin lymphoma. *Blood*, 2024, 144, 1992.
- Sedykh, S. E. – Prinz, V. V. – Buneva, V. N., et al.: Bispecific antibodies: design, therapy, perspectives. *Drug Des Devel Ther*, 2018, 12, s. 195–208.
- Minson, A. G. – Dickinson, M. J.: New bispecific antibodies in diffuse large B-cell lymphoma. *Haematol*. Dostupné z: <https://doi.org/10.3324/haematol.2024.285343>, vyhledáno 2. 7. 2025.
- Hutchings, M. – Morschhauser, F. – Iacoboni, G., et al.: Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. *J Clin Oncol*, 2021, 39, s. 1959–1970.
- Hutchings, M. – Mous, R. – Clausen, M. R., et al.: Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. *Lancet*, 2021, 398, s. 1157–1169.
- Olaszewski, A. J. – Avigdor, A. – Babu, S., et al.: Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. *Blood*, 2020, 136, s. 43–45.
- Thieblemont, C. – Phillips, T. – Ghesquieres, H., et al.: Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. *J Clin Oncol*, 2023, 41, s. 2238–2247.
- Rosenthal, A. – Jun, M. – Munoz, J., et al.: P1149: comparison of the efficacy of epcoritamab versus chimeric antigen receptor therapies, polatuzumab-based regimens, and tafasitamab-based regimens. *HemaSphere*, 2023. doi: 10.1097/01.H59.0000971492.92995.27.
- Linton, K. M. – Vitolo, U. – Jurczak, W., et al.: Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. *Lancet Haematol*, 2024, 11, s. e593–e605.
- Brooks, T. R. – Zabor, E. C. – Bedelu, Y. B., et al.: Real-world outcomes with bispecific T-cell engagers (REALBITE) for relapsed or refractory large B-cell lymphoma: a multi-center, retrospective cohort study. *Blood*, 2024, 144, 111.
- Yanashima, K. – Furukawa, Y. – Ishii, M., et al.: Early epcoritamab administration revives CAR-T cells in relapsed/refractory B-cell lymphomas. *EHaem*, 2025, 6, e70079.
- Morschhauser, F. – Belada, D. – Duell, J., et al.: Epcore DLBCL-3 first disclosure: fixed-duration epcoritamab monotherapy in older ( $\geq 75$  y), anthracycline-ineligible patients with previously untreated large B-cell lymphoma. *Blood*, 2024, 144, 867.
- Hutchings, M. – Iacoboni, G. – Morschhauser, F., et al.: CD20-Tcb (RG6026), a novel "2:1" format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma: preliminary results from a phase I first in human trial. *Blood*, 2018, 132, 226.
- Hutchings, M. – Carlo-Stella, C. – Morschhauser, F., et al.: Glofitamab Monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. *Blood*, 2023, 142, 433.
- Guiron, R. – Guz, D. – Kedmi, M., et al.: Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study. *Ann Hematol*, 2025, dostupné z: <https://doi.org/10.1007/s00277-025-06438-3>, vyhledáno 2. 7. 2025.
- Cartron, G. – Houot, R. – Al Tabaa, Y., et al.: Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study. *Nat Cancer*, 2025, doi: 10.1038/s43018-025-00941-2
- Phillips, T. J. – Carlo-Stella, C. – Morschhauser, F., et al.: Glofitamab in relapsed/refractory mantle cell lymphoma: results from a phase I/II study. *J Clin Oncol*, 2025, 43, s. 318–328.
- Budde, L. E. – Sehn, L. H. – Matasar, M., et al.: Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. *Lancet Oncol*, 2022, 23, s. 1055–1065.
- Bartlett, N. L. – Sehn, L. H. – Matasar, M. J., et al.: Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received  $\geq 2$  prior therapies: updated results from a pivotal phase II study. *Blood*, 2022, 140, s. 1467–1470.
- Bartlett, N. L. – Assouline, S. – Giri, P., et al.: Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv*, 2023, 7, s. 4926–4935.
- Bannerji, R. – Arnason, J. E. – Advani, R. H., et al.: Odronexitamab, a human CD20x $\alpha$ CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. *Lancet Haematol*, 2022, 9, e327–e339.
- Jagadeesh, D. – Tazsner, M. – Chong, G., et al.: Long-term follow-up of the phase 2 ELM-2 study: Odronexitamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). *J Clin Oncol*, 2025, 43, 7049.
- Topp, M. S. – Matasar, M. – Allan, J. N., et al.: Odronexitamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. *Blood*, 2025, 145, s. 1498–1509.
- Abramson, J. S. – Ku, M. – Hertzberg, M., et al.: Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. *Lancet*, 2024, 404, s. 1940–1954.
- Brody, J. D. – Jørgensen, J. – Belada, D., et al.: Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. *Blood*, 2025, 145, s. 1621–1631.
- Hutchings, M. – Dickinson, M. J. – Gritti, G., et al.: Engulfusp alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r/R B-NHL: extended follow up analysis of the dose-escalation part of phase 1 trial BP41072. *Blood*, 2024, 144, 990.
- Korfi, K. – Wilson, S. – Jiang, Z., et al.: CD19-CD28 (RO7443904) combination with glofitamab enhances T-cell proliferation and effector function in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). *Blood*, 2024, 144, 644.
- Rivero, A. – Mozas, P. – Magnano, L., et al.: Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. *Front Oncol*, 2023, 13, 1170394.
- Hou, J.-Z. – Jacobs, R. – Cho, S.-G., et al.: Interim results of the phase 1 study of Tnb-486, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) B-NHL. *Blood*, 2022, 140, s. 1474–1475.
- Sam, J. – Hofer, T. – Kuetzell, C., et al.: RG6333 (CD19-CD28), a CD19-targeted affinity-optimized CD28 bispecific antibody, enhances and prolongs the anti-tumor activity of glofitamab (CD20-TCB) in preclinical models. *Blood*, 2022, 140, s. 3142–3143.
- Herter, S. – Sam, J. – Ferrara Koller, C., et al.: RG6076 (CD19-4-1BBL): CD19-targeted 4-1BB ligand combination with glofitamab as an off-the-shelf, enhanced T-cell redirection therapy for B-cell malignancies. *Blood*, 2020, 136, 40.
- Lu, H. – Oka, A. – Coulson, M., et al.: PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD22 trispecific antibody for the treatment of B cell malignancies. *Blood*, 2022, 140, 3148.
- Reville, P. – Dai, E. – Sheikh, I., et al.: P1366: SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T-cell activity against large B-cell lymphoma. *HemaSphere*, doi: 10.1097/01.H59.0000972352.86009.7f.
- Townsend, W. – Leong, S. – Tucker, D., et al.: First-in-human phase I trial of a ROR1 targeting bispecific T cell engager (NVG-111) in combination with ibritinib or as monotherapy in subjects with relapsed refractory chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). *Blood*, 2022, 140, s. 4162–4163.
- Kater, A. P. – Van De Donk, N. W. C. J. – Rodriguez-Otero, P., et al.: Lava-051, a novel bispecific gamma-delta T-cell engager (gamma-body), in relapsed/refractory MM and CLL: pharmacodynamic and early clin data. *Blood*, 2022, 140, suppl. 1, s. 4608–4609.
- Oostindie, S. C. – Alemdehy, M. F. – Janmaat, M. L., et al.: Duo-body-CD3xCD30 demonstrates potent anti-tumor activity in pre-clinical models of CD30+ hematologic malignancies. *Blood*, 2022, 140, s. 3153–3154.
- Rothe, A. – Sasse, S. – Topp, M. S., et al.: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2015, 125, s. 4024–4031.
- Sasse, S. – Bröckelmann, P. J. – Momotow, J., et al.: AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. *Leuk Lymphoma*, 2022, 63, s. 1871–1878.
- Bartlett, N. L. – Herrera, A. F. – Domingo-Domenech, E., et al.: A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2020, 136, s. 2401–2409.
- Kerbaui, L. N. – Marin, N. D. – Kaplan, M., et al.: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies. *Clin Cancer Res*, 2021, 27, s. 3744–3756.
- Crochet, G. – Iacoboni, G. – Couturier, S., et al.: Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. *Blood*, 2024, 144, s. 334–338.
- Carlo-Stella, C. – Hutchings, M. – Offner, F., et al.: Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter's transformation. *Hematol Oncol*, 2023, 41, s. 63–65.
- Morschhauser, F. – Carlo-Stella, C. – Dickinson, M., et al.: Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). *Blood*, 2021, 138, 128.
- Sesques, P. – Houot, R. – Al Tabaa, Y., et al.: Glofitamab monotherapy in patients with non-Hodgkin B-cell lymphoma after failing CAR T-cell infusion: primary analysis of the Bicar study, a phase II LySA study. *Blood*, 2023, 142, 893.
- Topp, M. S. – Tani, M. – Dickinson, M., et al.: Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): A 12-month analysis from a phase Ib study. *Blood*, 2023, 142, 3085.
- Dickinson, M. – Viardot, A. – Marks, R., et al.: Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study. *J Clin Oncol*, 2023, 41, 7549.
- Minson, A. – Verner, E. – Giri, P., et al.: Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients  $\leq 65$  years of age with high-risk DLBCL: Interim analysis of Coalition. *Hematol Oncol*, 2023, 41, s. 421–422.
- Falchi, L. – Offner, F. – de Vos, S., et al.: Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: long-term results from the Epcore NHL-2 Trial. *Blood*, 2024, 144, 581.
- Alan Kerr, D. – Lavie, D. – Avigdor, A., et al.: ABCL-417 first data from subcutaneous epcoritamab + polatuzumab vedotin rituximab, cyclophosphamide doxorubicin, and prednisone (Pola-RCHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5. *Clin Lymphoma Myeloma Leuk*, 2024, 24, s. S478–S479.
- Olaszewski, A. J. – Phillips, T. J. – Hoffmann, M. S., et al.: Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. *Blood Adv*, 2023, 7, s. 6055–6065.
- Olaszewski, A. J. – Eradat, H. – Avigdor, A., et al.: Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit/frail patients with previously untreated diffuse large B-cell lymphoma. *Blood*, 2023, 142, 855.
- Leslie, L. A. – Cheah, C. Y. – Morschhauser, F., et al.: Fixed-duration epcoritamab + R-Mini-CHOP in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: updated results from Arm 8 of the Epcore NHL-2 Trial. *Blood*, 2024, 144, 3106.
- Karimi, Y. – Abrisqueta, P. – de Vos, S., et al.: Epcoritamab + R-DHAX-/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). *J Clin Oncol*, 2024, 42, 7032.
- Guiron, R. – Avivi Mazza, I. – Thieblemont, C., et al.: Fixed-duration epcoritamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL): updated results from Arm 1 of the Epcore NHL-5 Trial. *Blood*, 2024, 144, 3110.
- Minard-Colin, V. – Andión Catalán, M. – Vinti, L., et al.: Glofitamab in combination with R-ICE chemoimmunotherapy or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: initial safety and efficacy results from the ongoing iMATRIX-GLO Study. *Blood*, 2024, 144, 6483.
- Hutchings, M. – Sureda Balari, A. – Bosch, F., et al.: Glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed/refractory (R/R) large B-cell lymphoma (LBCL) including high-grade B-cell lymphoma (HGBCL): Extend. *Blood*, 2024, 144, 988.
- Budde, L. E. – Olaszewski, A. J. – Assouline, S., et al.: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. *Nat Med*, 2024, 30, s. 229–239.
- Koh, Y. – Byun, J. M. – Hong, J., et al.: Glofitamab combined with poseltinib and lenalidomide for relapsed/refractory diffuse large B cell lymphoma: Interim analysis of GPL study. *J Clin Oncol*, 2024, 42, 7066.
- Hutchings, M. – Gritti, G. – Sureda, A., et al.: CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma. *Blood*, 2019, 134, 2871.
- Falchi, L. – Sureda Balari, A. – Leppä, S., et al.: Fixed-duration Epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from Arm 2 of the Epcore NHL-2 Trial. *Blood*, 2024, 144, 342.

# Možnosti terapie CAR-T v léčbě lymfomů v roce 2025 v České republice

MUDr. František Folber, Ph.D. Interní hematologická a onkologická klinika, FN Brno a LF MU, Česká společnost pro genovou a buněčnou terapii, ČLS JEP

MUDr. Martina Filipová Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno

- Rosenbaum, L.: Tragedy, perseverance, and chance – the story of CAR-T therapy. *N Engl J Med*, 2017, 377, s. 1313–1315.
- Yun, K. – Siegler, E. L. – Kenderian, S. S.: Who wins the combat, CAR or TCR? *Leukemia*, 2023, 37, s. 1953–1962.
- Cappell, K. M. – Kochenderfer, J. N.: Long-term outcomes following CAR T cell therapy: what we know so far. *Nat Rev Clin Oncol*, 2023, 20, s. 359–371.
- Folber, F. – Mrkvová, Z. – Filipová, M.: Management nežádoucích účinků CAR-T terapie. *Farmakoterapie*, 2025, 21, s. 236–243.
- Státní ústav pro kontrolu léčiv. Praha. Poslední revize textu 3/2025.
- Kýmriah, SPC. Státní ústav pro kontrolu léčiv, Praha. Poslední revize textu 11/2024.
- Abecma, SPC. Státní ústav pro kontrolu léčiv. Praha. Poslední revize textu 11/2024.
- Hayden, P. J. – Roddie, C. – Bader, P., et al.: Management of adults and children receiving CAR-T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the Joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA). *Ann Oncol*, 2022, 33, s. 259–275.
- Belada, D. – Trněný, M., a kolektiv autorů Kooperativní lymfomové skupiny: Diagnostické a léčebné postupy u nemocných s maligními lymfomy; XV. vydání, Hradec Králové, 2025. Dostupné z: [https://www.lymphoma.cz/\\_uploads/attachments/Lecebna\\_doporuceni\\_2025\\_interaktivni\\_obsah\\_-\\_final.pdf](https://www.lymphoma.cz/_uploads/attachments/Lecebna_doporuceni_2025_interaktivni_obsah_-_final.pdf), vyhledáno 27. 6. 2025.
- Folber, F. – Pytlík, R. – Polgárová, K., et al.: Buněčná terapie – T-lymfocyty s chimickým antigenním receptorem (CAR-T). In: Doubek, M. – Mayer, J. (eds): *Červená kniha – Léčebné postupy v hematologii 2025*. Dostupné z: <https://www.hematology.cz/cervena-kniha-lecebne-postupy-v-hematologii/>, vyhledáno 27. 6. 2025.
- Alaggio, R. – Amador, C. – Anagnostopoulos, I., et al.: The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. *Leukemia*, 2022, 36, s. 1720–1748.
- Friedberg, J. W.: Relapsed/refractory diffuse large B-cell lymphoma. *Hematology Am Soc Hematol Educ Program*, 2011, 2011, s. 498–505.
- Neelapu, S. S. – Locke, F. L. – Bartlett, N. L., et al.: Axicabtagene ciloleucel CAR-T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*, 2017, 377, s. 2531–2544.
- Schuster, S. J. – Bishop, M. R. – Tam, C. S., et al.: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*, 2019, 380, s. 45–56.
- Abramson, J. S. – Palomba, M. L. – Gordon, L. I., et al.: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet*, 2020, 396, s. 839–852.
- Locke, F. L. – Miklos, D. B. – Jacobson, C. A., et al.: Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 640–654.
- Bishop, M. R. – Dickinson, M. – Purtil, D., et al.: Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 629–639.
- Kamdar, M. – Solomon, S. R. – Arnason, J., et al.: Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*, 2022, 399, s. 2294–2308.
- Houot, R. – Bachy, E. – Cartron, G., et al.: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. *Nat Med*, 2023, 29, s. 2593–2601.
- Sehgal, A. – Hoda, D. – Riedel, P. A., et al.: Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. *Lancet Oncol*, 2022, 23, s. 1066–1077.
- Jacobson, C. A. – Munoz, J. – Sun, F., et al.: Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. *Transplant Cell Ther*, 2024, 30, s. 77.e1–77.e15.
- Velkobuněčné B-lymfomy (LBCL). In: Belada, D. – Trněný, M.: *Diagnostické a léčebné postupy u nemocných s maligními lymfomy*; XV. vydání, Hradec Králové, 2025. Dostupné z: [https://www.lymphoma.cz/\\_uploads/attachments/Lecebna\\_doporuceni\\_2025\\_interaktivni\\_obsah\\_-\\_final.pdf](https://www.lymphoma.cz/_uploads/attachments/Lecebna_doporuceni_2025_interaktivni_obsah_-_final.pdf), vyhledáno 27. 6. 2025.
- Westin, J. – Sehn, L. H.: CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? *Blood*, 2022, 139, s. 2737–2746.
- Folikulární lymfom. In: Belada, D. – Trněný, M.: *Diagnostické a léčebné postupy u nemocných s maligními lymfomy*; XV. vydání, Hradec Králové, 2025. Dostupné z: [https://www.lymphoma.cz/\\_uploads/attachments/Lecebna\\_doporuceni\\_2025\\_interaktivni\\_obsah\\_-\\_final.pdf](https://www.lymphoma.cz/_uploads/attachments/Lecebna_doporuceni_2025_interaktivni_obsah_-_final.pdf), vyhledáno 27. 6. 2025.
- Jacobson, C. A. – Chavez, J. C. – Sehgal, A. R., et al.: Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*, 2022, 23, s. 91–103.
- Fowler, N. H. – Dickinson, M. – Dreyling, M., et al.: Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*, 2022, 28, s. 325–332.
- Morschhauser, F. – Dahiya, S. – Palomba, M. L., et al.: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. *Nat Med*, 2024, 30, s. 2199–2207.
- Iacoboni, G. – Morschhauser, F.: Building the future management of follicular lymphoma with T-cell-redirecting strategies. *Blood*, 2025, 145, s. 170–175.
- Lymfom z pláštových buněk – mantle cell lymphoma (MCL). In: Belada, D. – Trněný, M.: *Diagnostické a léčebné postupy u nemocných s maligními lymfomy*; XV. vydání, Hradec Králové, 2025. Dostupné z: [https://www.lymphoma.cz/\\_uploads/attachments/Lecebna\\_doporuceni\\_2025\\_interaktivni\\_obsah\\_-\\_final.pdf](https://www.lymphoma.cz/_uploads/attachments/Lecebna_doporuceni_2025_interaktivni_obsah_-_final.pdf), vyhledáno 27. 6. 2025.
- Wang, M. – Munoz, J., et al.: KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*, 2020, 382, s. 1331–1342.
- Wang, M. – Siddiqi, T. – Gordon, L. I., et al.: Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. *J Clin Oncol*, 2024, 42, s. 1146–1157.
- Dreger, P. – Ahmed, S. – Bazarbachi, A., et al.: How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives. *Bone Marrow Transplant*, 2025, 60, s. 759–768.
- Kittai, A. S. – Bond, D. – Huang, Y., et al.: Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study. *J Clin Oncol*, 2024, 42, s. 2071–2079.
- Samples, L. – Sadrzadeh, H. – Frigault, M. J., et al.: Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. *Blood*, 2025, 145, s. 2762–2767.
- Maciocia, N. – Wade, B. – Maciocia, P.: CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? *Blood Adv*, 2025, 9, s. 913–923.
- Meng, F. – Xiang, M. – Liu, Y., et al.: Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis. *BMC Cancer*, 2025, 25, 78.
- Yescarta, SPC. Státní ústav pro kontrolu léčiv. Praha. Poslední revize textu 8/2024.
- Breyanzi, SPC. Státní ústav pro kontrolu léčiv. Praha. Poslední revize textu 3/2025.

## Kam se posouvá léčba nemocných s nehodgkinskými lymfomy v roce 2025

doc. MUDr. David Belada, Ph.D. IV. interní hematologická klinika, LF UK a FN Hradec Králové

- Coyle, L. – Seymour, J. F. – Feugier, P., et al.: Glofitamab, a CD20xCD3 bispecific antibody, in patients with relapsed or refractory B-cell lymphomas: results from phase 1 study. *Blood*, 2020, 136, supplement 1, s. 20–21.
- Neelapu, S. S. – Locke, F. L. – Bartlett, N. L., et al.: Axicabtagene ciloleucel CAR-T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*, 2017, 377, s. 2531–2544.
- Ibrahim, N. – Hunter, T. – Khot, A., et al.: Emerging targeted therapies in non-Hodgkin lymphoma. *Cancer Treat Rev*, 2021, 96, 102186.
- Morschhauser, F. – Salles, G. – Bartlett, N. L., et al.: Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a phase 1/2 study. *Lancet Oncol*, 2021, 22, s. 291–301.
- Scott, D. W. – Mottok, A. – Ennishi, D., et al.: Prognostic significance of molecular subtypes in diffuse large B-cell lymphoma: the role of GCB and ABC classification. *Blood*, 2015, 125, s. 2015–2021.
- Locke, F. L. – Ghabadi, A. – Jacobson, C. A., et al.: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol*, 2019, 20, s. 31–42.
- Brudno, J. N. – Kochenderfer, J. N.: Toxicities of chimeric antigen receptor T cells: recognition and management. *Blood*, 2016, 127, s. 3321–3330.
- Buchbinder, E. I. – Desai, A.: CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. *Am J Clin Oncol*, 2016, 39, s. 98–106.
- Roschewski, M. – Dunleavy, K. – Pittaluga, S., et al.: Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a prospective, multicentre, observational cohort study. *Lancet Oncol*, 2015, 16, s. 541–549.
- Kurtz, D. M. – Green, M. R. – Bratman, S. V., et al.: Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. *Blood*, 2015, 125, s. 3679–3687.
- Tilly, H. – Morschhauser, F. – Sehn, L. H., et al.: Polatumumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 351–363.
- Salles, G. – Connors, J. M. – Rodríguez-Pinilla, S. M., et al.: Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*, 2021, 22, s. 790–800.
- Pro, B. – Advani, R. – Brice, P., et al.: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol*, 2012, 30, s. 2190–2196.

## Terapeutická zkušenost s ponatinibem u pacienta s refrakterní chronickou myeloidní leukémií – kazuistika

MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie, 1. LF UK, Praha

- Jabbour, E. – Kantarjian, H.: CML: Chronic myeloid leukemia: 2025 update on diagnosis, therapy and monitoring. *Am J Hematol*, 2024, 99, s. 2191–2212.
- Jabbour, E. – Apperley, J. – Cortes, J., et al.: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. *Leukemia*, 2024, 38, s. 475–481.
- Cortes, J. E. – Kim, D.-W. – Pinilla-Ibarz, J., et al.: Long-term results from the optic trial: a dose-optimization study of 3 starting doses of ponatinib. *Blood*, 2023, 142, suppl. 1, 3164.
- Kantarjian, H. M. – Jabbour, E. – Deininger, M., et al.: Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. *Am J Hematol*, 2022, 97, s. 1419–1426.
- Hochhaus, A. – Rea, D. – Boquimpani, C., et al.: Asciminib vs.

## Dosažení stabilní odpovědi na terapii fostamatinibem u pacienta s multirefrakterní imunitní trombocytopenií – kazuistika

MUDr. Eva Konířová I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- 1 Kozák, T., et al.: Doporučení ČHS pro diagnostiku a léčbu imunitní trombocytopenie dospělých (ITP). *Transfuzní Hematologie Dnes*, 2023, 1, s. 68–77.
- 2 Tavlesse. Platné SPC přípravku.
- 3 Rodeghiero, F., et al.: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood*, 2009, 113, s. 2386–2393.
- 4 Arnold, D. M., et al.: Refractory immune thrombocytopenia in adults: Towards a new definition. *Br J Haematol*, 2023, 203, s. 23–27.
- 5 Mahévas, M., et al.: How we manage immune thrombocytopenia in the elderly. *Br J Haematol*, 2016, 173, s. 844–856.
- 6 Portielje, J. E., et al.: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. *Blood*, 2001, 97, s. 2549–2554.
- 7 Busse, J. B., et al.: Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol*, 2018, 93, s. 921–930.
- 8 Busse, J. B., et al.: Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. *Am J Hematol*, 2019, 94, s. 546–553.
- 9 Zaja, F., et al.: How does real-life treatment with fostamatinib compare with the FIT1 and FIT2 studies? Results from the Italian GIMEMA study. Prezentováno na kongresu EHA 2025, 12.–15. 6. 2025, Milán, Itálie.
- 10 Cooper, N., et al.: Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. *Ther Adv Hematol*, 2021, 12, 20406207211010875.

## Molekulární diagnostika hematoonkologických onemocnění: zkušenosti z laboratoře GHC Genetics

Mgr. Tomáš Píš | Mgr. Kristýna Hanuláková GHC Genetics, s. r. o., Praha

- 1 Barbui, T. – Thiele, J. – Gisslinger, H., et al.: The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer Journal*, 2018, 8, s. 15, doi: 10.1038/s41408-018-0054-y.
- 2 Jia, R. – Kralovics, R.: Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. *Int J Hematol*, 2020, 111, s. 182–191, doi: 10.1007/s12185-019-02778-9.
- 3 Doubek, M. – Mayer, J.: Léčebné postupy v hematologii – aktualizace 2022. Doporučení České hematologické společnosti České lékařské

společnosti Jana Evangelisty Purkyně, 2022. Dostupné z: [www.hematology.cz/wp-content/uploads/2022/03/Doporučení\\_CHS\\_CLS\\_JEP-Cervena\\_kniha-2022-03-03.pdf](http://www.hematology.cz/wp-content/uploads/2022/03/Doporučení_CHS_CLS_JEP-Cervena_kniha-2022-03-03.pdf), vyhledáno 8. 10. 2025

## Bispecifické protilátky v léčbě folikulárního lymfomu

MUDr. Pavla Štěpánková IV. interní hematologická klinika, LF UK a FN Hradec Králové

- 1 Sant, M. – Allemani, C. – Tereanu, C., et al.: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood*, 2010, 116, 3724.
- 2 Junlén, H. R. – Peterson, S. – Kimby, E., et al.: Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. *Leukemia*, 2015, 29, 668.
- 3 Freedman, A. – Jacobsen, E.: Follicular lymphoma: 2020 update on diagnosis and management. *Am J Hematol*, 2020, 95, s. 316–327.
- 4 Shirley, M. H. – Sayeed, S. – Barnes, I., et al.: Incidence of haematological malignancies by ethnic group in England, 2001–7. *Br J Haematol*, 2013, 163, s. 465–477.
- 5 Anderson, T. – Chabner, B. A. – Young, R. C., et al.: Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. *Cancer*, 1982, 50, s. 2699–2707.
- 6 Martin, A. R. – Weisenburger, D. D. – Chan, W. C., et al.: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. *Blood*, 1995, 85, s. 3671–3678.
- 7 Horning, S. J.: Follicular lymphoma, survival, and rituximab: is it time to declare victory? *J Clin Oncol*, 2008, 26, s. 4537–4538.
- 8 Casulo, C. – Byrtek, M. – Dawson, K. L., et al.: Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. *J Clin Oncol*, 2015, 33, s. 2516–2522.
- 9 Patel, K. – Michot, J.-M. – Chanan-Khan, A. A., et al.: Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. *Blood*, 2019, 134, suppl. 1, s. 4079–4079.
- 10 Budde, L. E. – Sehn, L. H. – Matasar, M. J., et al.: Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received  $\geq 2$  prior lines of therapy: pivotal results from a phase I/II study. *Blood*, 2021, 138, suppl. 1, 127.
- 11 Morschhauser, F. – Bishton, M. – Eyre, T. A., et al.: Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular lymphoma: initial results from a phase Ib study. *Blood*, 2021, 138, suppl. 1, 129.
- 12 Morschhauser, F. – Carlo-Stella, C. – Dickinson, M., et al.: Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). *Blood*, 2021, 138, suppl. 1, 128.
- 13 Hutchings, M. – Mous, R. – Clausen, M. R., et al.: Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. *Lancet*, 2021, 398, s. 1157–1169.
- 14 Bannerji, R. – Allan, J. N. – Arnason, J. E., et al.: Odronextamab (REGN1979), a Human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CART therapy. *Blood*, 2020, 136, suppl. 1, s. 42–43.
- 15 Budde, L. E. – Sehn, L. H. – Matasar, M., et al.: Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. *Lancet Oncol*, 2022, 23, s. 1055–1065.
- 16 Sehn, L. H. – Bartlett, N. L. – Matasar, M. J., et al.: Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after  $\geq 2$  prior therapies. *Blood*, 2025, 145, s. 708–719.
- 17 Shadman, M. – Bartlett, N. L. – Matasar, M., et al.: Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after  $\geq 2$  prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. *Blood*, 2024, 144, suppl. 1, s. 4407–4407.
- 18 Linton, K. M. – Vitolo, U. – Jurczak, W., et al.: Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. *Lancet Haematol*, 2024, 11, s. e593–e605.
- 19 Thieblemont, C. – Karimi, Y. H. – Ghesquieres, H., et al.: Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. *Leukemia*, 2024, 38.
- 20 Kim, T. M. – Tazsner, M. – Novelli, S., et al.: Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. *Ann Oncol*, 2024, 35, 1208.
- 21 Major, A. – Kamdar, M.: Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. *Hematology Am Soc Hematol Educ Program*, 2023, s. 370–381.
- 22 de Assis, L. H. – El Fassi, D. – Hutchings, M.: Bispecific antibody therapies. *Hematology Am Soc Hematol Educ Program*, 2023, 2023, s. 216–222.
- 23 Thieblemont, C. – Phillips, T. – Ghesquieres, H., et al.: Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. *J Clin Oncol*, 2023, 41, s. 2238–2247.
- 24 Falchi, L. – Sureddu Balarì, A. – Leppä, S., et al.: Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the epcore NHL-2 trial. *Blood*, 2024, 144, suppl. 1, 342.
- 25 Brody, J. – Falchi, L. – Vitolo, U., et al.: Fixed-duration epcoritamab in combination with bendamustine + rituximab for first-line treatment of follicular lymphoma: initial results from epcore NHL-2 arm 3. *Blood*, 2024, 144, suppl. 1, 1627.
- 26 Lee, D. W. – Santomaso, B. D. – Locke, F. L., et al.: ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant*, 2019, 25, s. 625–638.
- 27 Thieblemont, C. – Phillips, T. – Ghesquieres, H., et al.: Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. *J Clin Oncol*, 2023, 41, s. 2238–2247.
- 28 Falchi, L. – Carlo-Stella, C. – Morschhauser, F., et al.: Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). *Blood*, 2023, 142, suppl. 1, 3130.
- 29 Bannerji, R. – Arnason, J. E. – Advani, R. H., et al.: Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. *Lancet Haematol*, 2022, 9, s. e327–e339.
- 30 Kim, W. S. – Kim, T. M. – Cho, S. G., et al.: Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2. *Blood*, 2022, 140, suppl. 1, s. 1070–1071.
- 31 de Assis, L. H. – El Fassi, D. – Hutchings, M.: Bispecific antibody therapies. *Hematology Am Soc Hematol Educ Program*, 2023, 2023, s. 216–222.
- 32 Mosunetuzumab product information. Dostupné z: [https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf), vyhledáno 7. 7. 2025.
- 33 Mosunetuzumab-axgb injection, for intravenous use. United States prescribing information. Revize 12/2022. US Food and Drug Administration, dostupné z: [https://www.accessdata.fda.gov/drugatfd\\_docs/label/2022/761263s000lbl.pdf](https://www.accessdata.fda.gov/drugatfd_docs/label/2022/761263s000lbl.pdf), vyhledáno 7. 7. 2025.
- 34 Assouline, S. – Bartlett, N. L. – Matasar, M., et al.: Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after  $\geq 3$  years of follow-up: subgroup analysis of a pivotal phase II study. Abstrakt S233 prezentována na kongresu European Hematology Association 2024, Madrid, Španělsko, 14. 6. 2024.
- 35 Nizamuddin, I. A. – Bartlett, N. L.: Bispecific antibodies in follicular lymphoma. *Haematologica*, 2025, 110, s. 1472–1482, doi: 10.3324/haematol.2024.285245.
- 36 Lewis, K. L. – Cheah, C. Y.: The value of bispecific antibodies in relapsed and refractory DLBCL. *Leukemia & Lymphoma*, 2024, 65, s. 720–735.